Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma

LESSONS LEARNED. Due to evolving imaging criteria in brain tumors and variation in magnetic resonance imaging evaluation, it is not ideal to use response rate as a primary objective. Future studies involving antiangiogenic agents should use overall survival. Disease‐expected toxicities should be con...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncologist
Huvudupphovsmän: Affronti, Mary Lou, Jackman, Jennifer Gamboa, McSherry, Frances, Herndon, James E., Massey, Elwood C., Lipp, Eric, Desjardins, Annick, Friedman, Henry S., Vlahovic, Gordana, Vredenburgh, James, Peters, Katherine B.
Materialtyp: Artigo
Språk:Inglês
Publicerad: AlphaMed Press 2018
Ämnen:
Clinical Trial Results
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6156179/
https://ncbi.nlm.nih.gov/pubmed/29666296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0149
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk